1C84 Grosso, Dolores - Thomas Jefferson University - Thomas Jefferson University
Dr. Grosso

Dolores Grosso, DNP, CRNP

Contact Dr. Grosso

834 Chestnut Street
Suite 315
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Posttreatment interleukin-2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?
  2. Recent advances in haploidentical stem cell transplantation
  3. Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host or Graft-versus-Graft Effects
  4. A two-step approach to allogeneic haploidentical hematopoietic stem cell transplantation
  5. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  6. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
  7. Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
  8. Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir
  9. Cytoprotection in acute myelogenous leukemia (AML) therapy
  10. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
  11. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
  12. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  13. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches
  14. High complete remission rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML
0